Data on the stability of darunavir/cobicistat suspension after tablet manipulation
Identifieur interne : 000477 ( Pmc/Checkpoint ); précédent : 000476; suivant : 000478Data on the stability of darunavir/cobicistat suspension after tablet manipulation
Auteurs : D. Zanon [Italie] ; A. Manca [Italie] ; A. De Nicol [Italie] ; A. D'Avolio [Italie] ; U. M. Musazzi [Italie] ; F. Cilurzo [Italie] ; N. Maximova [Italie] ; C. Tomasello [Italie] ; P. Minghetti [Italie]Source :
- Data in Brief [ 2352-3409 ] ; 2020.
Abstract
The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed combination, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Unfortunately, for most of them, the drug products available on the market are not designed to be administered by a nasogastric tube to inpatients of intensive care units. Therefore, their manipulation, even if it can strongly affect the product quality, is necessary for the preparation of suspension to meet patients’ need. In this situation, it is urgent to provide data and guidance to support hospital pharmacists and clinicians in their activity. The data in this article indicate that darunavir/cobicistat suspensions compounded by pharmacists using as active ingredient a commercially available tablet can be stable at least for one week.
Url:
DOI: 10.1016/j.dib.2020.105552
PubMed: NONE
PubMed Central: 7168728
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:7168728Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Data on the stability of darunavir/cobicistat suspension after tablet manipulation</title><author><name sortKey="Zanon, D" sort="Zanon, D" uniqKey="Zanon D" first="D." last="Zanon">D. Zanon</name><affiliation wicri:level="1"><nlm:aff id="aff0001">Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste</wicri:regionArea><wicri:noRegion>Trieste</wicri:noRegion></affiliation></author><author><name sortKey="Manca, A" sort="Manca, A" uniqKey="Manca A" first="A." last="Manca">A. Manca</name><affiliation wicri:level="3"><nlm:aff id="aff0002">Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="De Nicol, A" sort="De Nicol, A" uniqKey="De Nicol A" first="A." last="De Nicol">A. De Nicol</name><affiliation wicri:level="3"><nlm:aff id="aff0002">Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="D Avolio, A" sort="D Avolio, A" uniqKey="D Avolio A" first="A." last="D'Avolio">A. D'Avolio</name><affiliation wicri:level="3"><nlm:aff id="aff0002">Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="Musazzi, U M" sort="Musazzi, U M" uniqKey="Musazzi U" first="U. M." last="Musazzi">U. M. Musazzi</name><affiliation wicri:level="1"><nlm:aff id="aff0003">Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Cilurzo, F" sort="Cilurzo, F" uniqKey="Cilurzo F" first="F." last="Cilurzo">F. Cilurzo</name><affiliation wicri:level="1"><nlm:aff id="aff0003">Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Maximova, N" sort="Maximova, N" uniqKey="Maximova N" first="N." last="Maximova">N. Maximova</name><affiliation wicri:level="1"><nlm:aff id="aff0001">Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste</wicri:regionArea><wicri:noRegion>Trieste</wicri:noRegion></affiliation></author><author><name sortKey="Tomasello, C" sort="Tomasello, C" uniqKey="Tomasello C" first="C." last="Tomasello">C. Tomasello</name><affiliation wicri:level="3"><nlm:aff id="aff0004">S.C. Farmacie Ospedaliere - Ospedale M. Vittoria - Asl Città di Torino, Turin, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>S.C. Farmacie Ospedaliere - Ospedale M. Vittoria - Asl Città di Torino, Turin</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="Minghetti, P" sort="Minghetti, P" uniqKey="Minghetti P" first="P." last="Minghetti">P. Minghetti</name><affiliation wicri:level="1"><nlm:aff id="aff0003">Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmc">7168728</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168728</idno><idno type="RBID">PMC:7168728</idno><idno type="doi">10.1016/j.dib.2020.105552</idno><idno type="pmid">NONE</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000289</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000289</idno><idno type="wicri:Area/Pmc/Curation">000289</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000289</idno><idno type="wicri:Area/Pmc/Checkpoint">000477</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000477</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Data on the stability of darunavir/cobicistat suspension after tablet manipulation</title><author><name sortKey="Zanon, D" sort="Zanon, D" uniqKey="Zanon D" first="D." last="Zanon">D. Zanon</name><affiliation wicri:level="1"><nlm:aff id="aff0001">Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste</wicri:regionArea><wicri:noRegion>Trieste</wicri:noRegion></affiliation></author><author><name sortKey="Manca, A" sort="Manca, A" uniqKey="Manca A" first="A." last="Manca">A. Manca</name><affiliation wicri:level="3"><nlm:aff id="aff0002">Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="De Nicol, A" sort="De Nicol, A" uniqKey="De Nicol A" first="A." last="De Nicol">A. De Nicol</name><affiliation wicri:level="3"><nlm:aff id="aff0002">Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="D Avolio, A" sort="D Avolio, A" uniqKey="D Avolio A" first="A." last="D'Avolio">A. D'Avolio</name><affiliation wicri:level="3"><nlm:aff id="aff0002">Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="Musazzi, U M" sort="Musazzi, U M" uniqKey="Musazzi U" first="U. M." last="Musazzi">U. M. Musazzi</name><affiliation wicri:level="1"><nlm:aff id="aff0003">Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Cilurzo, F" sort="Cilurzo, F" uniqKey="Cilurzo F" first="F." last="Cilurzo">F. Cilurzo</name><affiliation wicri:level="1"><nlm:aff id="aff0003">Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Maximova, N" sort="Maximova, N" uniqKey="Maximova N" first="N." last="Maximova">N. Maximova</name><affiliation wicri:level="1"><nlm:aff id="aff0001">Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste</wicri:regionArea><wicri:noRegion>Trieste</wicri:noRegion></affiliation></author><author><name sortKey="Tomasello, C" sort="Tomasello, C" uniqKey="Tomasello C" first="C." last="Tomasello">C. Tomasello</name><affiliation wicri:level="3"><nlm:aff id="aff0004">S.C. Farmacie Ospedaliere - Ospedale M. Vittoria - Asl Città di Torino, Turin, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>S.C. Farmacie Ospedaliere - Ospedale M. Vittoria - Asl Città di Torino, Turin</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="Minghetti, P" sort="Minghetti, P" uniqKey="Minghetti P" first="P." last="Minghetti">P. Minghetti</name><affiliation wicri:level="1"><nlm:aff id="aff0003">Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author></analytic><series><title level="j">Data in Brief</title><idno type="eISSN">2352-3409</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed combination, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Unfortunately, for most of them, the drug products available on the market are not designed to be administered by a nasogastric tube to inpatients of intensive care units. Therefore, their manipulation, even if it can strongly affect the product quality, is necessary for the preparation of suspension to meet patients’ need. In this situation, it is urgent to provide data and guidance to support hospital pharmacists and clinicians in their activity. The data in this article indicate that darunavir/cobicistat suspensions compounded by pharmacists using as active ingredient a commercially available tablet can be stable at least for one week.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Minghetti, P" uniqKey="Minghetti P">P. Minghetti</name></author><author><name sortKey="Pantano, D" uniqKey="Pantano D">D. Pantano</name></author><author><name sortKey="Gennari, C G M" uniqKey="Gennari C">C.G.M. Gennari</name></author><author><name sortKey="Casiraghi, A" uniqKey="Casiraghi A">A. Casiraghi</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="D Avolio, A" uniqKey="D Avolio A">A. D'Avolio</name></author><author><name sortKey="Baietto, L" uniqKey="Baietto L">L. Baietto</name></author><author><name sortKey="Siccardi, M" uniqKey="Siccardi M">M. Siccardi</name></author><author><name sortKey="Sciandra, M" uniqKey="Sciandra M">M. Sciandra</name></author><author><name sortKey="Simiele, M" uniqKey="Simiele M">M. Simiele</name></author><author><name sortKey="Oddone, V" uniqKey="Oddone V">V. Oddone</name></author><author><name sortKey="Bonora, S" uniqKey="Bonora S">S. Bonora</name></author><author><name sortKey="Di Perri, G" uniqKey="Di Perri G">G. Di Perri</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="data-paper"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Data Brief</journal-id><journal-id journal-id-type="iso-abbrev">Data Brief</journal-id><journal-title-group><journal-title>Data in Brief</journal-title></journal-title-group><issn pub-type="epub">2352-3409</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">7168728</article-id><article-id pub-id-type="publisher-id">S2352-3409(20)30446-7</article-id><article-id pub-id-type="doi">10.1016/j.dib.2020.105552</article-id><article-id pub-id-type="publisher-id">105552</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology, Toxicology and Pharmaceutical Science</subject></subj-group></article-categories><title-group><article-title>Data on the stability of darunavir/cobicistat suspension after tablet manipulation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Zanon</surname><given-names>D.</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Manca</surname><given-names>A.</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0003"><name><surname>De Nicolò</surname><given-names>A.</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0004"><name><surname>D'Avolio</surname><given-names>A.</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0005"><name><surname>Musazzi</surname><given-names>U.M.</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0006"><name><surname>Cilurzo</surname><given-names>F.</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0007"><name><surname>Maximova</surname><given-names>N.</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0008"><name><surname>Tomasello</surname><given-names>C.</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0009"><name><surname>Minghetti</surname><given-names>P.</given-names></name><email>paola.minghetti@unimi.it</email><xref rid="aff0003" ref-type="aff">c</xref><xref rid="cor0001" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="aff0001"><label>a</label>Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy</aff><aff id="aff0002"><label>b</label>Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy</aff><aff id="aff0003"><label>c</label>Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy</aff><aff id="aff0004"><label>d</label>S.C. Farmacie Ospedaliere - Ospedale M. Vittoria - Asl Città di Torino, Turin, Italy</aff><author-notes><corresp id="cor0001"><label>⁎</label>Corresponding author. <email>paola.minghetti@unimi.it</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>12</day><month>4</month><year>2020</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="collection"><month>6</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>12</day><month>4</month><year>2020</year></pub-date><volume>30</volume><elocation-id>105552</elocation-id><history><date date-type="received"><day>27</day><month>3</month><year>2020</year></date><date date-type="rev-recd"><day>3</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>6</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>© 2020 The Author(s). Published by Elsevier Inc.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder></copyright-holder><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0001"><p>The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed combination, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Unfortunately, for most of them, the drug products available on the market are not designed to be administered by a nasogastric tube to inpatients of intensive care units. Therefore, their manipulation, even if it can strongly affect the product quality, is necessary for the preparation of suspension to meet patients’ need. In this situation, it is urgent to provide data and guidance to support hospital pharmacists and clinicians in their activity. The data in this article indicate that darunavir/cobicistat suspensions compounded by pharmacists using as active ingredient a commercially available tablet can be stable at least for one week.</p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Covid-19</kwd><kwd>Medicament manipulation</kwd><kwd>Nasogastric tube</kwd><kwd>Darunavir</kwd><kwd>Cobicistat</kwd></kwd-group></article-meta></front></pmc><affiliations><list><country><li>Italie</li></country><region><li>Lombardie</li><li>Piémont</li></region><settlement><li>Milan</li><li>Turin</li></settlement></list><tree><country name="Italie"><noRegion><name sortKey="Zanon, D" sort="Zanon, D" uniqKey="Zanon D" first="D." last="Zanon">D. Zanon</name></noRegion><name sortKey="Cilurzo, F" sort="Cilurzo, F" uniqKey="Cilurzo F" first="F." last="Cilurzo">F. Cilurzo</name><name sortKey="D Avolio, A" sort="D Avolio, A" uniqKey="D Avolio A" first="A." last="D'Avolio">A. D'Avolio</name><name sortKey="De Nicol, A" sort="De Nicol, A" uniqKey="De Nicol A" first="A." last="De Nicol">A. De Nicol</name><name sortKey="Manca, A" sort="Manca, A" uniqKey="Manca A" first="A." last="Manca">A. Manca</name><name sortKey="Maximova, N" sort="Maximova, N" uniqKey="Maximova N" first="N." last="Maximova">N. Maximova</name><name sortKey="Minghetti, P" sort="Minghetti, P" uniqKey="Minghetti P" first="P." last="Minghetti">P. Minghetti</name><name sortKey="Musazzi, U M" sort="Musazzi, U M" uniqKey="Musazzi U" first="U. M." last="Musazzi">U. M. Musazzi</name><name sortKey="Tomasello, C" sort="Tomasello, C" uniqKey="Tomasello C" first="C." last="Tomasello">C. Tomasello</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000477 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000477 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:7168728
|texte= Data on the stability of darunavir/cobicistat suspension after tablet manipulation
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:NONE" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |